Yang Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yang Li has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Zhenqing Hou
School of Pharmaceutical Sciences, Institute of Materia Medica, Xinjiang University, Urumqi, 830017, China
16 shared publications Jinyan Lin
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou 350025 P. R. China
11 shared publicationsFukai Zhu
Department of Gynecology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361015, China
9 shared publicationsHaina Tian
Department of Biomaterials
8 shared publicationsYilin Chen
Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361005, PR China
7 shared publicationsZhongxiong Fan
Department of Biomaterials, College of Materials, Research Center of Biomedical Engineering of Xiamen & Key Laboratory of Biomedical Engineering of Fujian Province, Xiamen University, Xiamen 361005, P. R. China
7 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Wiley in Advanced Science
Dual Suppression of Oxidative Stress and JAK/STAT3 Signaling Attenuates Inflammation‐Driven Corneal Neovascularization
Corneal neovascularization (CoNV) is a vision‐threatening disorder driven by persistent oxidative stress and inflammation, yet effective therapies targeting these interconnected pathological processes remain limited. Here, we identify enhanced signal transducer and activator of transcription 3 (STAT3) phosphorylation and inflammatory signaling in corneal samples from patients with CoNV, as well as reactive oxygen species (ROS) accumulation and macrophage infiltration were observed in an alkali burn‐induced mouse model. To address these pathological features, we developed Sta@MSR, a macrophage membrane‐cloaked biomimetic nanozyme integrating ruthenium‐mediated ROS scavenging with Stattic‐mediated STAT3 inhibition. Mechanistically, Sta@MSR attenuated oxidative stress and STAT3‐associated inflammatory signaling, thereby suppressing endothelial angiogenic activity and pathological neovascularization. Furthermore, macrophage membrane cloaking enhanced ocular retention and corneal penetration, facilitating topical delivery. Importantly, Sta@MSR markedly reduced pathological neovascularization and inflammatory injury, restored corneal transparency, and exhibited favorable ocular and systemic biocompatibility. Collectively, this work highlights coordinated regulation of oxidative stress and STAT3 signaling as a promising therapeutic strategy for inflammation‐driven CoNV.
- 10 November 2026
- Published by Wiley in Advanced Science
Open AccessDual Suppression of Oxidative Stress and JAK/STAT3 Signaling Attenuates Inflammation‐Driven Corneal Neovascularization
Corneal neovascularization (CoNV) is a vision‐threatening disorder driven by persistent oxidative stress and inflammation, yet effective therapies targeting these interconnected pathological processes remain limited. Here, we identify enhanced signal transducer and activator of transcription 3 (STAT3) phosphorylation and inflammatory signaling in corneal samples from patients with CoNV, as well as reactive oxygen species (ROS) accumulation and macrophage infiltration were observed in an alkali burn‐induced mouse model. To address these pathological features, we developed Sta@MSR, a macrophage membrane‐cloaked biomimetic nanozyme integrating ruthenium‐mediated ROS scavenging with Stattic‐mediated STAT3 inhibition. Mechanistically, Sta@MSR attenuated oxidative stress and STAT3‐associated inflammatory signaling, thereby suppressing endothelial angiogenic activity and pathological neovascularization. Furthermore, macrophage membrane cloaking enhanced ocular retention and corneal penetration, facilitating topical delivery. Importantly, Sta@MSR markedly reduced pathological neovascularization and inflammatory injury, restored corneal transparency, and exhibited favorable ocular and systemic biocompatibility. Collectively, this work highlights coordinated regulation of oxidative stress and STAT3 signaling as a promising therapeutic strategy for inflammation‐driven CoNV.
- Open Access
- 31 October 2026
- Published by Wiley in Advanced Science
Ultrasound‐Activated Ce(IV)‐Integrated Biomimetic Nanoplatform for Oxygenation‐Reinforced Gas‐Sonodynamic Ferroptosis and cGAS–STING‐Driven Antitumor Immunity
Immunologically “cold” tumors remain poorly responsive to immunotherapy because hypoxia‐limited oxidative therapy, insufficient immunogenic tumor‐cell death, and dysfunctional T‐cell responses restrict the transition from local tumor destruction to systemic antitumor immunity. Here, an ultrasound‐responsive Ce(IV)‐integrated biomimetic nanoplatform, TcEM@Ce‐P4CO@M, is developed to address these barriers. Ce 4+ /Ce 3+ redox cycling promotes H 2 O 2 decomposition and O 2 generation, sustaining ultrasound‐triggered reactive oxygen species production under hypoxic conditions. Concurrently, P4CO‐derived carbon monoxide contributes to mitochondrial oxidative stress and lipid peroxidation. Endogenous iron‐homeostasis remodeling and impairment of the SLC7A11/glutathione (GSH)/glutathione peroxidase 4 (GPX4) antioxidant defense further favor ferroptosis‐associated tumor‐cell injury. Mitochondrial dysfunction and DNA damage are accompanied by enhanced stimulator of interferon genes (STING)‐associated signaling, while co‐delivered MSA‐2 further reinforces STING‐mediated innate immune activation, collectively contributing to an immunogenic environment that supports dendritic‐cell maturation. The engineered tumor‐derived membrane promotes tumor‐associated delivery and provides CD86‐mediated costimulation and anti‐TIM‐3‐mediated checkpoint modulation. In 4T1 tumor models, this coordinated cascade suppresses primary tumors, inhibits non‐irradiated distant tumors, reduces experimental pulmonary metastatic burden, and remodels the tumor immune microenvironment. Collectively, TcEM@Ce‐P4CO@M converts hypoxia‐limited local sonodynamic injury into ferroptosis‐linked innate‐to‐adaptive systemic antitumor immunity.
- 31 October 2026
- Published by Wiley in Advanced Science
Open AccessUltrasound‐Activated Ce(IV)‐Integrated Biomimetic Nanoplatform for Oxygenation‐Reinforced Gas‐Sonodynamic Ferroptosis and cGAS–STING‐Driven Antitumor Immunity
Immunologically “cold” tumors remain poorly responsive to immunotherapy because hypoxia‐limited oxidative therapy, insufficient immunogenic tumor‐cell death, and dysfunctional T‐cell responses restrict the transition from local tumor destruction to systemic antitumor immunity. Here, an ultrasound‐responsive Ce(IV)‐integrated biomimetic nanoplatform, TcEM@Ce‐P4CO@M, is developed to address these barriers. Ce 4+ /Ce 3+ redox cycling promotes H 2 O 2 decomposition and O 2 generation, sustaining ultrasound‐triggered reactive oxygen species production under hypoxic conditions. Concurrently, P4CO‐derived carbon monoxide contributes to mitochondrial oxidative stress and lipid peroxidation. Endogenous iron‐homeostasis remodeling and impairment of the SLC7A11/glutathione (GSH)/glutathione peroxidase 4 (GPX4) antioxidant defense further favor ferroptosis‐associated tumor‐cell injury. Mitochondrial dysfunction and DNA damage are accompanied by enhanced stimulator of interferon genes (STING)‐associated signaling, while co‐delivered MSA‐2 further reinforces STING‐mediated innate immune activation, collectively contributing to an immunogenic environment that supports dendritic‐cell maturation. The engineered tumor‐derived membrane promotes tumor‐associated delivery and provides CD86‐mediated costimulation and anti‐TIM‐3‐mediated checkpoint modulation. In 4T1 tumor models, this coordinated cascade suppresses primary tumors, inhibits non‐irradiated distant tumors, reduces experimental pulmonary metastatic burden, and remodels the tumor immune microenvironment. Collectively, TcEM@Ce‐P4CO@M converts hypoxia‐limited local sonodynamic injury into ferroptosis‐linked innate‐to‐adaptive systemic antitumor immunity.
- Open Access
- 1 July 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 61, 464-481
Natural killer cell-inspired dendritic mesoporous rare-earth nanoparticles potentiate X-ray-triggered reactive oxygen generation for low-dose radiotherapy-radiodynamic therapy
The efficacy of traditional radiotherapy has been significantly limited by its severe side effects, tumor hypoxia, and insufficient tumor accumulation. To address these challenges, we developed a multifarious radio enhancer composed of NK cell-derived extracellular vesicle (NKEV)-cloaked dendritic mesoporous thulium oxide (Tm2O3) encapsulated with cerium clusters (Ce6C)-photosensitizer (TSSI) coordination (TSSI-Ce6C-DMTm@NKEV). This nanoplatform is designed to heighten X-ray absorption and energy transfer while generating oxygen to alleviate tumor hypoxia, thereby improving radiotherapy-radiodynamic therapy. Once accumulated at tumor sites, the TSSI-Ce6C-DMTm@NKEV nanoparticles could actively recognize the tumor cells and then catalyze endogenous hydrogen peroxide (H2O2) to produce oxygen, thereby increasing oxygen supply and alleviating tumor hypoxia. Upon X-ray irradiation, the nanoparticles could significantly enhance hydroxyl radical (•OH) generation from Ce6C-DMTm for high-efficiency radiotherapy via matching between Tm's K-edge with X-ray bremsstrahlung peak, and synchronously facilitate singlet oxygen (1O2) generation from adjacently coordinated TSSI for radiodynamic therapy. This dual mechanism of action, integrated with the alleviation of tumor hypoxia, leads to superior anticancer outcomes through lipid peroxidation, mitochondrial dysfunction, and DNA double-strand break. Our work demonstrates a potential radiotherapy strategy that leverages low-dose X-ray to intensify tumor suppression while minimizing systemic toxicity.
- 1 July 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 61, 464-481
Open AccessNatural killer cell-inspired dendritic mesoporous rare-earth nanoparticles potentiate X-ray-triggered reactive oxygen generation for low-dose radiotherapy-radiodynamic therapy
The efficacy of traditional radiotherapy has been significantly limited by its severe side effects, tumor hypoxia, and insufficient tumor accumulation. To address these challenges, we developed a multifarious radio enhancer composed of NK cell-derived extracellular vesicle (NKEV)-cloaked dendritic mesoporous thulium oxide (Tm2O3) encapsulated with cerium clusters (Ce6C)-photosensitizer (TSSI) coordination (TSSI-Ce6C-DMTm@NKEV). This nanoplatform is designed to heighten X-ray absorption and energy transfer while generating oxygen to alleviate tumor hypoxia, thereby improving radiotherapy-radiodynamic therapy. Once accumulated at tumor sites, the TSSI-Ce6C-DMTm@NKEV nanoparticles could actively recognize the tumor cells and then catalyze endogenous hydrogen peroxide (H2O2) to produce oxygen, thereby increasing oxygen supply and alleviating tumor hypoxia. Upon X-ray irradiation, the nanoparticles could significantly enhance hydroxyl radical (•OH) generation from Ce6C-DMTm for high-efficiency radiotherapy via matching between Tm's K-edge with X-ray bremsstrahlung peak, and synchronously facilitate singlet oxygen (1O2) generation from adjacently coordinated TSSI for radiodynamic therapy. This dual mechanism of action, integrated with the alleviation of tumor hypoxia, leads to superior anticancer outcomes through lipid peroxidation, mitochondrial dysfunction, and DNA double-strand break. Our work demonstrates a potential radiotherapy strategy that leverages low-dose X-ray to intensify tumor suppression while minimizing systemic toxicity.
- 29 June 2026
- Published by Elsevier in Biomaterials
- Vol. 336, 124413
Genetically programmed engineered nanodevices trigger cascade reinforcement between AMPK and cGAS-STING activation for colon cancer sonoimmunotherapy
- 29 June 2026
- Published by Elsevier in Biomaterials
- Vol. 336, 124413
Genetically programmed engineered nanodevices trigger cascade reinforcement between AMPK and cGAS-STING activation for colon cancer sonoimmunotherapy
- Open Access
- 9 April 2026
- Published by Elsevier in SSRN Electronic Journal
Genetically Programmed Engineered Nanodevices Trigger Cascade Reinforcement between AMPK and cGAS-STING Activation for Colon Cancer Sonoimmunotherapy
Immune checkpoint blockade (ICB) has shown clinical promise in cancer immunotherapy, but colorectal cancer (CRC) remains difficult to treat due to a complex immunosuppressive tumor microenvironment (TIME). This TIME features dysregulated CD47/SIRPα and PD-1/PD-L1 pathways, T cell exhaustion, and infiltration of immunosuppressive cells. Therefore, novel strategies to reshape TIME are critically needed. Here we developed bioinspired nanodevices (SPCM@DMgTi-ADM) for CRC immunotherapy. These nanodevices consist of dendritic titanium-magnesium nanoparticles (DMgTi) that serve as both a sonosensitizer and a carrier for aldometanib (ADM). The nanoparticles are coated with genetically engineered membranes displaying SIRPα and PD-1 decoy receptors (SPCM). This design achieves cascade reinforcement between AMPK activation and cGAS-STING activation. The SPCM coating simultaneously blocks SIRPα/CD47 and PD-1/PD-L1 axes, preliminarily reshaping the TIME. Released Mg2+ induces conformational changes in LFA-1 on CD8+ T cells, promoting their tumor infiltration and cytotoxic function. Mg2+ also acts as a cofactor to enhance ADM-induced AMPK activation, which together with sonodynamic therapy (SDT) drives autophagy-dependent ferroptosis. This synergistic process triggers strong immunogenic cell death (ICD). The released dsDNA potently activates the cGAS-STING pathway, which in turn inhibits GPX4 and sustains ferroptotic stress. This creates a self-amplifying loop: ferroptosis promotes dsDNA release, which activates cGAS-STING signaling; STING then suppresses GPX4, worsens ferroptosis and further boosting anti-tumor immunity. Both in vitro and in vivo studies confirm that our nanodevice effectively evaluates tumors and activates systemic anti-tumor immunity, offering a clinically translatable strategy for precision CRC therapy.
- 9 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessGenetically Programmed Engineered Nanodevices Trigger Cascade Reinforcement between AMPK and cGAS-STING Activation for Colon Cancer Sonoimmunotherapy
Immune checkpoint blockade (ICB) has shown clinical promise in cancer immunotherapy, but colorectal cancer (CRC) remains difficult to treat due to a complex immunosuppressive tumor microenvironment (TIME). This TIME features dysregulated CD47/SIRPα and PD-1/PD-L1 pathways, T cell exhaustion, and infiltration of immunosuppressive cells. Therefore, novel strategies to reshape TIME are critically needed. Here we developed bioinspired nanodevices (SPCM@DMgTi-ADM) for CRC immunotherapy. These nanodevices consist of dendritic titanium-magnesium nanoparticles (DMgTi) that serve as both a sonosensitizer and a carrier for aldometanib (ADM). The nanoparticles are coated with genetically engineered membranes displaying SIRPα and PD-1 decoy receptors (SPCM). This design achieves cascade reinforcement between AMPK activation and cGAS-STING activation. The SPCM coating simultaneously blocks SIRPα/CD47 and PD-1/PD-L1 axes, preliminarily reshaping the TIME. Released Mg2+ induces conformational changes in LFA-1 on CD8+ T cells, promoting their tumor infiltration and cytotoxic function. Mg2+ also acts as a cofactor to enhance ADM-induced AMPK activation, which together with sonodynamic therapy (SDT) drives autophagy-dependent ferroptosis. This synergistic process triggers strong immunogenic cell death (ICD). The released dsDNA potently activates the cGAS-STING pathway, which in turn inhibits GPX4 and sustains ferroptotic stress. This creates a self-amplifying loop: ferroptosis promotes dsDNA release, which activates cGAS-STING signaling; STING then suppresses GPX4, worsens ferroptosis and further boosting anti-tumor immunity. Both in vitro and in vivo studies confirm that our nanodevice effectively evaluates tumors and activates systemic anti-tumor immunity, offering a clinically translatable strategy for precision CRC therapy.
- Open Access
- 20 February 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102937
Rare-earth cerium-coordinated ICG nanoprobe for tumor hypoxia relief and intensified photodynamic therapy
- 20 February 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102937
Open AccessRare-earth cerium-coordinated ICG nanoprobe for tumor hypoxia relief and intensified photodynamic therapy
- Open Access
- 5 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10880
NIR-IIb fluorescence ratiometric imaging of tumor-associated neutrophils for immunotherapy efficacy monitoring and strategy optimization
Imaging the immune activation status of tumor-associated neutrophils (TANs) provides insights into cancer immunotherapeutic strategy improvement. Here we show a ratiometric nanoprobe responding to tumor microenvironment and enabling NIR-IIb quantitative fluorescence imaging of TANs with overexpression of neutrophil elastase (NE). The ratiometric nanoprobe integrates erbium-based nanoparticles (ErNPs) with NE-cleavable peptide-caged near-infrared-II (NIR-II) fluorescence dye. Upon systemic delivery, the nanoprobe actively targets tumor microenvironment, where NE cleaves the caging peptide to trigger energy transfer within ErNPs under 808 nm excitation, yielding enhanced NIR-IIb fluorescence emission at 1532 nm. In contrast, the NE-independent fluorescence of ErNPs at 1532 nm remains stable when excited at 980 nm, providing a self-calibrated signal. Across Hepa1-6 and H22 tumor models during immunotherapy, the nanoprobe translates TANs' phenotype shift into precise ratiometric signals, enabling quantitative dynamic imaging of TANs' immune status changes. Subsequently, the responders to immunotherapy among mice could be effectively identified by fluorescence ratiometric imaging of TANs. This strategy offers a non-invasive way to track immune status in real time and could guide timely adjustments to immunotherapy strategies, potentially improving outcomes for patients.
- 5 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10880
Open AccessNIR-IIb fluorescence ratiometric imaging of tumor-associated neutrophils for immunotherapy efficacy monitoring and strategy optimization
Imaging the immune activation status of tumor-associated neutrophils (TANs) provides insights into cancer immunotherapeutic strategy improvement. Here we show a ratiometric nanoprobe responding to tumor microenvironment and enabling NIR-IIb quantitative fluorescence imaging of TANs with overexpression of neutrophil elastase (NE). The ratiometric nanoprobe integrates erbium-based nanoparticles (ErNPs) with NE-cleavable peptide-caged near-infrared-II (NIR-II) fluorescence dye. Upon systemic delivery, the nanoprobe actively targets tumor microenvironment, where NE cleaves the caging peptide to trigger energy transfer within ErNPs under 808 nm excitation, yielding enhanced NIR-IIb fluorescence emission at 1532 nm. In contrast, the NE-independent fluorescence of ErNPs at 1532 nm remains stable when excited at 980 nm, providing a self-calibrated signal. Across Hepa1-6 and H22 tumor models during immunotherapy, the nanoprobe translates TANs' phenotype shift into precise ratiometric signals, enabling quantitative dynamic imaging of TANs' immune status changes. Subsequently, the responders to immunotherapy among mice could be effectively identified by fluorescence ratiometric imaging of TANs. This strategy offers a non-invasive way to track immune status in real time and could guide timely adjustments to immunotherapy strategies, potentially improving outcomes for patients.
- 22 September 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 387, 114254
Virus-inspired nanozymes for two-dimensional biomimetic penetration and long-acting ferroptosis inhibition in treating dry eye disease
- 22 September 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 387, 114254
Virus-inspired nanozymes for two-dimensional biomimetic penetration and long-acting ferroptosis inhibition in treating dry eye disease
- Open Access
- 14 February 2025
- Published by Wiley in Advanced Science
- Vol. 12 (14) , e2413385
A Hf(IV)‐Coordinated NIR‐II Fluorescence “Turn‐On” Nanoprobe for Precise Imaging‐Guided Surgery in Breast Cancer
Breast‐conserving surgery (BCS) has become the standard care for early‐stage breast cancer. The accurate assessment of tumor margins is urgently required for BCS because positive resection margins often lead to local recurrence. To address this clinical dilemma, a Hf(IV)‐coordinated NIR‐II fluorescence “turn‐on” nanoprobe based on the clinically approved NIR‐II fluorescent dye indocyanine green (ICG) for intraoperative tumor visualization is developed. Notably, the fluorescence of ICG can be efficiently quenched by Hf(IV) and subsequently recovered in vivo, showing a remarkable fluorescence “quenching‐recovery‐amplification” capacity. This nanoprobe can effectively accumulate in tumor sites, accurately identifying submillimeter‐sized primary and residual tumors with high sensitivity. In addition, subcutaneous, muscle‐infiltrating, and orthotopic breast cancer models are built to repeatedly prove that this ultrasensitive nanoprobe is feasible for precise imaging‐guided surgery in breast cancer. Overall, this study constructs an activatable fluorescent nanoprobe for real‐time intraoperative tumor margin visualization, holding promise for complete surgical resection and reduction of local recurrence.
- 14 February 2025
- Published by Wiley in Advanced Science
- Vol. 12 (14) , e2413385
Open AccessA Hf(IV)‐Coordinated NIR‐II Fluorescence “Turn‐On” Nanoprobe for Precise Imaging‐Guided Surgery in Breast Cancer
Breast‐conserving surgery (BCS) has become the standard care for early‐stage breast cancer. The accurate assessment of tumor margins is urgently required for BCS because positive resection margins often lead to local recurrence. To address this clinical dilemma, a Hf(IV)‐coordinated NIR‐II fluorescence “turn‐on” nanoprobe based on the clinically approved NIR‐II fluorescent dye indocyanine green (ICG) for intraoperative tumor visualization is developed. Notably, the fluorescence of ICG can be efficiently quenched by Hf(IV) and subsequently recovered in vivo, showing a remarkable fluorescence “quenching‐recovery‐amplification” capacity. This nanoprobe can effectively accumulate in tumor sites, accurately identifying submillimeter‐sized primary and residual tumors with high sensitivity. In addition, subcutaneous, muscle‐infiltrating, and orthotopic breast cancer models are built to repeatedly prove that this ultrasensitive nanoprobe is feasible for precise imaging‐guided surgery in breast cancer. Overall, this study constructs an activatable fluorescent nanoprobe for real‐time intraoperative tumor margin visualization, holding promise for complete surgical resection and reduction of local recurrence.